CAI vs TEM
CAI: Caris Life Sciences delivers comprehensive molecular profiling and precision medicine insights to optimize oncology treatment and drug development. TEM: Tempus AI leverages a massive library of multimodal clinical and molecular data to power AI-driven precision medicine for patients and researchers.
Side-by-side fundamentals
| Metric | CAI | TEM | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $27.50 | $69.28 | |
| Market cap | $7.8B | $9.8B | |
| P/E as of 2026-10-08 | 74.97 | n/a | |
| Net margin FY2025, SEC XBRL | -8.4% | -19.3% | CAI higher |
| Operating margin FY2025, SEC XBRL | +5.6% | -19.9% | CAI higher |
| ROE FY2025, SEC XBRL | -11.8% | -49.9% | CAI higher |
| ROA FY2025, SEC XBRL | -6.0% | -10.8% | CAI higher |
| Debt / equity as of 2026-09-03 | 0.66 | 3.06 | CAI lower |
| Revenue growth (YoY) as of 2026-09-03 | +38.5% | +50.4% | TEM higher |
| Revenue CAGR (3y) SEC XBRL | +62.9% | +58.3% | CAI higher |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | 1.27 | 2.69 | |
| 1-year return as of 2026-10-08 close | -16.5% | -32.9% | CAI higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.